{"transactions":[{"id":1049691,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-03T10:04:03.000Z","date":"2025-08-28","kind":"sale","planned":false,"acquired":false,"shares":6572,"price":1.97,"value":12946.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a \"sell to cover\" provision included in each RSU Agreement in connection with the vesting of restricted stock unit (\"RSUs\") that were granted to the Reporting Person on August 26, 2021."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a \"sell to cover\" provision included in each RSU Agreement in connection with the vesting of restricted stock unit (\"RSUs\") that were granted to the Reporting Person on August 26, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":703294,"source":{"system":"sec-edgar","filing":"0000950170-25-112661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017025112661/ownership.xml","form_type":"4"}},{"id":1109820,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T00:32:05.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 12, 2026, subject to the Reporting Person's continued service through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":709866,"source":{"system":"sec-edgar","filing":"0000950170-25-087021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017025087021/ownership.xml","form_type":"4"}},{"id":1281879,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-06T01:30:24.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":55260,"price":0.78,"value":43102.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a \"sell to cover\" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":689866,"source":{"system":"sec-edgar","filing":"0000950170-25-014849","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017025014849/ownership.xml","form_type":"4"}},{"id":1281878,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-06T01:30:24.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":13959,"price":0.78,"value":10888.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a \"sell to cover\" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":745126,"source":{"system":"sec-edgar","filing":"0000950170-25-014849","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017025014849/ownership.xml","form_type":"4"}},{"id":1419948,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-29T22:43:37.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":5912,"price":1.35,"value":7981.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a \"sell to cover\" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on August 26, 2021."}],"balance_after":759085,"source":{"system":"sec-edgar","filing":"0000950170-24-102000","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017024102000/ownership.xml","form_type":"4"}},{"id":1497882,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-30T20:25:29.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on May 29, 2025, subject to the Reporting Person's continued service through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":764997,"source":{"system":"sec-edgar","filing":"0000950170-24-066625","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017024066625/ownership.xml","form_type":"4"}},{"id":1658959,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-06T01:50:09.000Z","date":"2024-02-02","kind":"sale","planned":false,"acquired":false,"shares":63795,"price":1.37,"value":87399.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\") that were granted to the Reporting Person on February 1, 2022 pursuant to a \"sell to cover\" provision included in the RSU Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $1.36 to $1.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":744997,"source":{"system":"sec-edgar","filing":"0000950170-24-011496","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017024011496/ownership.xml","form_type":"4"}},{"id":1762597,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-10T21:18:36.000Z","date":"2023-10-05","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on October 5, 2024, subject to the Reporting Person's continued service through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":808792,"source":{"system":"sec-edgar","filing":"0000950170-23-052692","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017023052692/ownership.xml","form_type":"4"}},{"id":1793062,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-30T20:21:03.000Z","date":"2023-08-28","kind":"sale","planned":false,"acquired":false,"shares":9040,"price":1.26,"value":11390.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\") that were granted to the Reporting Person on August 26, 2021 pursuant to a \"sell to cover\" provision included in the RSU Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":788792,"source":{"system":"sec-edgar","filing":"0000950170-23-045442","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017023045442/ownership.xml","form_type":"4"}},{"id":2030629,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-02-06T21:15:11.000Z","date":"2023-02-03","kind":"sale","acquired":false,"shares":12286,"price":1.81,"value":22237.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\") that were granted to the Reporting Person on February 1, 2022 pursuant to a \"sell to cover\" provision included in the RSU Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 691,205 RSUs held by the Reporting Person."}],"balance_after":797832,"source":{"system":"sec-edgar","filing":"0000899243-23-004039","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924323004039/doc4.xml","form_type":"4"}},{"id":2033060,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-02-04T00:38:32.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":531914,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2024, subject to the Reporting Person's continued service through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 691,205 RSUs held by the Reporting Person."}],"balance_after":810118,"source":{"system":"sec-edgar","filing":"0000899243-23-003939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924323003939/doc4.xml","form_type":"4"}},{"id":2414051,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-03T21:18:13.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":187730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":187730,"derivative":{"exercise_price":11.18,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":187730},"source":{"system":"sec-edgar","filing":"0000899243-22-004591","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924322004591/doc4.xml","form_type":"4"}},{"id":2414050,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2022-02-03T21:18:13.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":134168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 212,387 RSUs held by the Reporting Person."}],"balance_after":278204,"source":{"system":"sec-edgar","filing":"0000899243-22-004591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924322004591/doc4.xml","form_type":"4"}},{"id":2457163,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-29T23:26:05.000Z","date":"2021-12-27","kind":"exercise","acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":486809,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0000899243-21-050049","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924321050049/doc4.xml","form_type":"4"}},{"id":2457162,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2021-12-29T23:26:05.000Z","date":"2021-12-27","kind":"sale","acquired":false,"shares":8000,"price":14.5833,"value":116666.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 8,000 shares)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.77 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 78,219 restricted stock units (\"RSUs\") held by the Reporting Person. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 26, 2022, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":144036,"source":{"system":"sec-edgar","filing":"0000899243-21-050049","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924321050049/doc4.xml","form_type":"4"}},{"id":2457161,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2021-12-29T23:26:05.000Z","date":"2021-12-27","kind":"exercise","acquired":true,"shares":8000,"price":5.9,"value":47200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 8,000 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 78,219 restricted stock units (\"RSUs\") held by the Reporting Person. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 26, 2022, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":152036,"source":{"system":"sec-edgar","filing":"0000899243-21-050049","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924321050049/doc4.xml","form_type":"4"}},{"id":2586626,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2021-08-30T20:15:43.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":78219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 26, 2022, subject to the Reporting Person's continued service through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":144036,"source":{"system":"sec-edgar","filing":"0000899243-21-034502","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924321034502/doc4.xml","form_type":"4"}},{"id":2881982,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-04T00:44:52.000Z","date":"2021-02-01","kind":"grant","acquired":true,"shares":179319,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest as to 25% on February 1, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":179319,"derivative":{"exercise_price":19.18,"expiration_date":"2031-02-01","underlying":"Common Stock","underlying_shares":179319},"source":{"system":"sec-edgar","filing":"0000899243-21-004783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924321004783/doc4.xml","form_type":"4"}},{"id":2991124,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-06T00:00:10.000Z","date":"2020-11-04","kind":"exercise","acquired":false,"shares":7370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":494809,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":7370},"source":{"system":"sec-edgar","filing":"0000899243-20-030490","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/doc4.xml","form_type":"4"}},{"id":2991123,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-06T00:00:10.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":2137,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":502179,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":2137},"source":{"system":"sec-edgar","filing":"0000899243-20-030490","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/doc4.xml","form_type":"4"}},{"id":2991122,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-11-06T00:00:10.000Z","date":"2020-11-04","kind":"sale","acquired":false,"shares":7370,"price":14.4281,"value":106335.097,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 9,507\nshares)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.63 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65817,"source":{"system":"sec-edgar","filing":"0000899243-20-030490","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/doc4.xml","form_type":"4"}},{"id":2991121,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-11-06T00:00:10.000Z","date":"2020-11-04","kind":"exercise","acquired":true,"shares":7370,"price":5.9,"value":43483.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 9,507\nshares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":73187,"source":{"system":"sec-edgar","filing":"0000899243-20-030490","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/doc4.xml","form_type":"4"}},{"id":2991120,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-11-06T00:00:10.000Z","date":"2020-11-03","kind":"sale","acquired":false,"shares":2137,"price":14.2675,"value":30489.6475,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 9,507\nshares)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.35 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65817,"source":{"system":"sec-edgar","filing":"0000899243-20-030490","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/doc4.xml","form_type":"4"}},{"id":2991119,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-11-06T00:00:10.000Z","date":"2020-11-03","kind":"exercise","acquired":true,"shares":2137,"price":5.9,"value":12608.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 9,507\nshares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":67954,"source":{"system":"sec-edgar","filing":"0000899243-20-030490","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/doc4.xml","form_type":"4"}},{"id":2999339,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-27T21:32:27.000Z","date":"2020-10-23","kind":"exercise","acquired":false,"shares":20,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":504316,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":20},"source":{"system":"sec-edgar","filing":"0000899243-20-029328","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320029328/doc4.xml","form_type":"4"}},{"id":2999338,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-10-27T21:32:27.000Z","date":"2020-10-23","kind":"sale","acquired":false,"shares":20,"price":14.25,"value":285.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 20 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65817,"source":{"system":"sec-edgar","filing":"0000899243-20-029328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320029328/doc4.xml","form_type":"4"}},{"id":2999337,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-10-27T21:32:27.000Z","date":"2020-10-23","kind":"exercise","acquired":true,"shares":20,"price":5.9,"value":118.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 20 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65837,"source":{"system":"sec-edgar","filing":"0000899243-20-029328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320029328/doc4.xml","form_type":"4"}},{"id":3006335,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-16T00:24:39.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":105,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":504336,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":105},"source":{"system":"sec-edgar","filing":"0000899243-20-028430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/doc4.xml","form_type":"4"}},{"id":3006334,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-16T00:24:39.000Z","date":"2020-10-13","kind":"exercise","acquired":false,"shares":14367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":504441,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":14367},"source":{"system":"sec-edgar","filing":"0000899243-20-028430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/doc4.xml","form_type":"4"}},{"id":3006333,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-10-16T00:24:39.000Z","date":"2020-10-14","kind":"sale","acquired":false,"shares":105,"price":14.25,"value":1496.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 14,472 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65817,"source":{"system":"sec-edgar","filing":"0000899243-20-028430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/doc4.xml","form_type":"4"}},{"id":3006332,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-10-16T00:24:39.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":105,"price":5.9,"value":619.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 14,472 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65922,"source":{"system":"sec-edgar","filing":"0000899243-20-028430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/doc4.xml","form_type":"4"}},{"id":3006331,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-10-16T00:24:39.000Z","date":"2020-10-13","kind":"sale","acquired":false,"shares":14367,"price":14.2836,"value":205212.4812,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 14,472 shares)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.52 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65817,"source":{"system":"sec-edgar","filing":"0000899243-20-028430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/doc4.xml","form_type":"4"}},{"id":3006330,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-10-16T00:24:39.000Z","date":"2020-10-13","kind":"exercise","acquired":true,"shares":14367,"price":5.9,"value":84765.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 14,472 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":80184,"source":{"system":"sec-edgar","filing":"0000899243-20-028430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/doc4.xml","form_type":"4"}},{"id":3034443,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-11T01:51:25.000Z","date":"2020-09-08","kind":"exercise","acquired":false,"shares":774,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":518808,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":774},"source":{"system":"sec-edgar","filing":"0000899243-20-024865","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320024865/doc4.xml","form_type":"4"}},{"id":3034442,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-09-11T01:51:25.000Z","date":"2020-09-08","kind":"sale","acquired":false,"shares":774,"price":14.2503,"value":11029.7322,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 774 shares)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.26 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65817,"source":{"system":"sec-edgar","filing":"0000899243-20-024865","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320024865/doc4.xml","form_type":"4"}},{"id":3034441,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-09-11T01:51:25.000Z","date":"2020-09-08","kind":"exercise","acquired":true,"shares":774,"price":5.9,"value":4566.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 774 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":66591,"source":{"system":"sec-edgar","filing":"0000899243-20-024865","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320024865/doc4.xml","form_type":"4"}},{"id":3085687,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-09T22:48:00.000Z","date":"2020-07-09","kind":"exercise","acquired":false,"shares":2293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":519582,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":2293},"source":{"system":"sec-edgar","filing":"0000899243-20-018847","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/doc4.xml","form_type":"4"}},{"id":3085686,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-09T22:48:00.000Z","date":"2020-07-07","kind":"exercise","acquired":false,"shares":754,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":521875,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":754},"source":{"system":"sec-edgar","filing":"0000899243-20-018847","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/doc4.xml","form_type":"4"}},{"id":3085685,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-07-09T22:48:00.000Z","date":"2020-07-09","kind":"sale","acquired":false,"shares":2293,"price":14.3073,"value":32806.6389,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 3,047 shares)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.37 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65817,"source":{"system":"sec-edgar","filing":"0000899243-20-018847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/doc4.xml","form_type":"4"}},{"id":3085684,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-07-09T22:48:00.000Z","date":"2020-07-09","kind":"exercise","acquired":true,"shares":2293,"price":5.9,"value":13528.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 3,047 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":68110,"source":{"system":"sec-edgar","filing":"0000899243-20-018847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/doc4.xml","form_type":"4"}},{"id":3085683,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-07-09T22:48:00.000Z","date":"2020-07-07","kind":"sale","acquired":false,"shares":754,"price":14.2506,"value":10744.9524,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 3,047 shares)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.285 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65817,"source":{"system":"sec-edgar","filing":"0000899243-20-018847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/doc4.xml","form_type":"4"}},{"id":3085682,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-07-09T22:48:00.000Z","date":"2020-07-07","kind":"exercise","acquired":true,"shares":754,"price":5.9,"value":4448.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 3,047 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":66571,"source":{"system":"sec-edgar","filing":"0000899243-20-018847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/doc4.xml","form_type":"4"}},{"id":3097597,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-30T01:21:20.000Z","date":"2020-06-25","kind":"exercise","acquired":false,"shares":2642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":522629,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":2642},"source":{"system":"sec-edgar","filing":"0001209191-20-039352","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/doc4.xml","form_type":"4"}},{"id":3097596,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-30T01:21:20.000Z","date":"2020-06-24","kind":"exercise","acquired":false,"shares":3880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":525271,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":3880},"source":{"system":"sec-edgar","filing":"0001209191-20-039352","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/doc4.xml","form_type":"4"}},{"id":3097595,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-30T01:21:20.000Z","date":"2020-06-23","kind":"exercise","acquired":false,"shares":8045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":529151,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":8045},"source":{"system":"sec-edgar","filing":"0001209191-20-039352","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/doc4.xml","form_type":"4"}},{"id":3097594,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-30T01:21:20.000Z","date":"2020-06-22","kind":"exercise","acquired":false,"shares":2613,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":537196,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":2613},"source":{"system":"sec-edgar","filing":"0001209191-20-039352","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/doc4.xml","form_type":"4"}},{"id":3097593,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-06-30T01:21:20.000Z","date":"2020-06-25","kind":"sale","acquired":false,"shares":2642,"price":14.2507,"value":37650.3494,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65817,"source":{"system":"sec-edgar","filing":"0001209191-20-039352","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/doc4.xml","form_type":"4"}},{"id":3097592,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-06-30T01:21:20.000Z","date":"2020-06-25","kind":"exercise","acquired":true,"shares":2642,"price":5.9,"value":15587.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":68459,"source":{"system":"sec-edgar","filing":"0001209191-20-039352","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/doc4.xml","form_type":"4"}},{"id":3097591,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-06-30T01:21:20.000Z","date":"2020-06-24","kind":"sale","acquired":false,"shares":3880,"price":14.2834,"value":55419.592,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65817,"source":{"system":"sec-edgar","filing":"0001209191-20-039352","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/doc4.xml","form_type":"4"}},{"id":3097590,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-06-30T01:21:20.000Z","date":"2020-06-24","kind":"exercise","acquired":true,"shares":3880,"price":5.9,"value":22892.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":69697,"source":{"system":"sec-edgar","filing":"0001209191-20-039352","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/doc4.xml","form_type":"4"}},{"id":3097589,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-06-30T01:21:20.000Z","date":"2020-06-23","kind":"sale","acquired":false,"shares":8045,"price":14.3274,"value":115263.933,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65817,"source":{"system":"sec-edgar","filing":"0001209191-20-039352","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/doc4.xml","form_type":"4"}},{"id":3097588,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-06-30T01:21:20.000Z","date":"2020-06-23","kind":"exercise","acquired":true,"shares":8045,"price":5.9,"value":47465.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":73862,"source":{"system":"sec-edgar","filing":"0001209191-20-039352","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/doc4.xml","form_type":"4"}},{"id":3097587,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-06-30T01:21:20.000Z","date":"2020-06-22","kind":"sale","acquired":false,"shares":2613,"price":14.2996,"value":37364.8548,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65817,"source":{"system":"sec-edgar","filing":"0001209191-20-039352","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/doc4.xml","form_type":"4"}},{"id":3097586,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-06-30T01:21:20.000Z","date":"2020-06-22","kind":"exercise","acquired":true,"shares":2613,"price":5.9,"value":15416.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":68430,"source":{"system":"sec-edgar","filing":"0001209191-20-039352","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/doc4.xml","form_type":"4"}},{"id":3294972,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-03T22:32:53.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest as to 25% on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":180000,"derivative":{"exercise_price":9.34,"expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0000899243-20-002617","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320002617/doc4.xml","form_type":"4"}},{"id":3713457,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-03T00:12:53.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest as to 25% on January 2, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":180000,"derivative":{"exercise_price":6.26,"expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0000899243-19-000175","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924319000175/doc4.xml","form_type":"4"}},{"id":3871855,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-07T01:41:52.000Z","date":"2018-07-06","kind":"exercise","acquired":false,"shares":1600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares underlying this option were fully vested as of July 6, 2017."}],"balance_after":118888,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":1600},"source":{"system":"sec-edgar","filing":"0000899243-18-019566","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/doc4.xml","form_type":"4"}},{"id":3871854,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-07T01:41:52.000Z","date":"2018-07-05","kind":"exercise","acquired":false,"shares":3076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares underlying this option were fully vested as of July 6, 2017."}],"balance_after":120488,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":3076},"source":{"system":"sec-edgar","filing":"0000899243-18-019566","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/doc4.xml","form_type":"4"}},{"id":3871853,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-07-07T01:41:52.000Z","date":"2018-07-06","kind":"sale","acquired":false,"shares":200,"price":17.92,"value":3584.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65817,"source":{"system":"sec-edgar","filing":"0000899243-18-019566","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/doc4.xml","form_type":"4"}},{"id":3871852,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-07-07T01:41:52.000Z","date":"2018-07-06","kind":"sale","acquired":false,"shares":200,"price":17.9,"value":3580.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":66017,"source":{"system":"sec-edgar","filing":"0000899243-18-019566","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/doc4.xml","form_type":"4"}},{"id":3871851,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-07-07T01:41:52.000Z","date":"2018-07-06","kind":"sale","acquired":false,"shares":100,"price":17.705,"value":1770.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":66217,"source":{"system":"sec-edgar","filing":"0000899243-18-019566","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/doc4.xml","form_type":"4"}},{"id":3871850,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-07-07T01:41:52.000Z","date":"2018-07-06","kind":"sale","acquired":false,"shares":100,"price":17.62,"value":1762.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":66317,"source":{"system":"sec-edgar","filing":"0000899243-18-019566","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/doc4.xml","form_type":"4"}},{"id":3871849,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-07-07T01:41:52.000Z","date":"2018-07-06","kind":"sale","acquired":false,"shares":400,"price":17.58,"value":7032.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":66417,"source":{"system":"sec-edgar","filing":"0000899243-18-019566","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/doc4.xml","form_type":"4"}},{"id":3871848,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-07-07T01:41:52.000Z","date":"2018-07-06","kind":"sale","acquired":false,"shares":100,"price":17.545,"value":1754.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":66817,"source":{"system":"sec-edgar","filing":"0000899243-18-019566","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/doc4.xml","form_type":"4"}},{"id":3871847,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-07-07T01:41:52.000Z","date":"2018-07-06","kind":"sale","acquired":false,"shares":500,"price":17.5,"value":8750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":66917,"source":{"system":"sec-edgar","filing":"0000899243-18-019566","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/doc4.xml","form_type":"4"}},{"id":3871846,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-07-07T01:41:52.000Z","date":"2018-07-06","kind":"exercise","acquired":true,"shares":1600,"price":5.9,"value":9440.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":67417,"source":{"system":"sec-edgar","filing":"0000899243-18-019566","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/doc4.xml","form_type":"4"}},{"id":3871845,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-07-07T01:41:52.000Z","date":"2018-07-05","kind":"sale","acquired":false,"shares":3076,"price":17.6215,"value":54203.734,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":65817,"source":{"system":"sec-edgar","filing":"0000899243-18-019566","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/doc4.xml","form_type":"4"}},{"id":3871844,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-07-07T01:41:52.000Z","date":"2018-07-05","kind":"exercise","acquired":true,"shares":3076,"price":5.9,"value":18148.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee."}],"balance_after":68893,"source":{"system":"sec-edgar","filing":"0000899243-18-019566","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/doc4.xml","form_type":"4"}},{"id":4130420,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75825,"kind":"person","name":"Mahadevia Ankit","position":1,"cik":"0001720974","reported_name":"Mahadevia Ankit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-15T21:05:29.000Z","date":"2017-12-13","kind":"grant","acquired":true,"shares":125079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest as to 25% on December 13, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":125079,"derivative":{"exercise_price":11.63,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":125079},"source":{"system":"sec-edgar","filing":"0000899243-17-028846","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924317028846/doc4.xml","form_type":"4"}}]}